Sumithira Vasu
Cited by
Cited by
Tagraxofusp in blastic plasmacytoid dendritic-cell neoplasm
N Pemmaraju, AA Lane, KL Sweet, AS Stein, S Vasu, W Blum, DA Rizzieri, ...
New England Journal of Medicine 380 (17), 1628-1637, 2019
Outcomes of allogeneic hematopoietic cell transplantation in patients with myelofibrosis with prior exposure to Janus kinase 1/2 inhibitors
M Shanavas, U Popat, LC Michaelis, V Fauble, D McLornan, R Klisovic, ...
Biology of Blood and Marrow Transplantation 22 (3), 432-440, 2016
Donor demographic and laboratory predictors of allogeneic peripheral blood stem cell mobilization in an ethnically diverse population
S Vasu, SF Leitman, JF Tisdale, MM Hsieh, RW Childs, AJ Barrett, ...
Blood, The Journal of the American Society of Hematology 112 (5), 2092-2100, 2008
Myeloid growth factors, version 2.2017, NCCN clinical practice guidelines in oncology
J Crawford, PS Becker, JO Armitage, DW Blayney, J Chavez, P Curtin, ...
Journal of the National Comprehensive Cancer Network 15 (12), 1520-1541, 2017
Ten-year outcome of patients with acute myeloid leukemia not treated with allogeneic transplantation in first complete remission
S Vasu, J Kohlschmidt, K Mrůzek, AK Eisfeld, D Nicolet, LJ Sterling, ...
Blood advances 2 (13), 1645-1650, 2018
Randomized phase III BMT CTN trial of calcineurin inhibitor–free chronic graft-versus-host disease interventions in myeloablative hematopoietic cell transplantation for†…
L Luznik, MC Pasquini, B Logan, RJ Soiffer, J Wu, SM Devine, N Geller, ...
Journal of Clinical Oncology 40 (4), 356, 2022
None of the above: thrombotic microangiopathy beyond TTP and HUS
C Masias, S Vasu, SR Cataland
Blood, The Journal of the American Society of Hematology 129 (21), 2857-2863, 2017
Biologic assignment trial of reduced-intensity hematopoietic cell transplantation based on donor availability in patients 50-75 years of age with advanced myelodysplastic syndrome
R Nakamura, W Saber, MJ Martens, A Ramirez, B Scott, B Oran, E Leifer, ...
Journal of clinical oncology 39 (30), 3328, 2021
MicroRNAs activate natural killer cells through Toll-like receptor signaling
S He, J Chu, LC Wu, H Mao, Y Peng, CA Alvarez-Breckenridge, T Hughes, ...
Blood, The Journal of the American Society of Hematology 121 (23), 4663-4671, 2013
Decitabine enhances anti-CD33 monoclonal antibody BI 836858–mediated natural killer ADCC against AML blasts
S Vasu, S He, C Cheney, B Gopalakrishnan, R Mani, G Lozanski, X Mo, ...
Blood, The Journal of the American Society of Hematology 127 (23), 2879-2889, 2016
NCCN guidelines insights: hematopoietic growth factors, version 1.2020: featured updates to the NCCN guidelines
PS Becker, EA Griffiths, LM Alwan, K Bachiashvili, A Brown, R Cool, ...
Journal of the National Comprehensive Cancer Network 18 (1), 12-22, 2020
Clinical activity of axicabtagene ciloleucel in adult patients with Richter syndrome
AS Kittai, DA Bond, B William, A Saad, S Penza, Y Efebera, K Larkin, ...
Blood Advances 4 (19), 4648-4652, 2020
Eculizumab therapy in adults with allogeneic hematopoietic cell transplant-associated thrombotic microangiopathy
S Vasu, H Wu, A Satoskar, M Puto, J Roddy, W Blum, R Klisovic, ...
Bone marrow transplantation 51 (9), 1241-1244, 2016
Decitabine priming enhances the antileukemic effects of exportin 1 (XPO1) selective inhibitor selinexor in acute myeloid leukemia
P Ranganathan, X Yu, R Santhanam, J Hofstetter, A Walker, K Walsh, ...
Blood, The Journal of the American Society of Hematology 125 (17), 2689-2692, 2015
MicroRNA-29b mediates altered innate immune development in acute leukemia
BL Mundy-Bosse, SD Scoville, L Chen, K McConnell, HC Mao, EH Ahmed, ...
The Journal of clinical investigation 126 (12), 4404-4416, 2016
Complement-mediated thrombotic microangiopathy as a link between endothelial damage and steroid-refractory GVHD
SA Wall, Q Zhao, M Yearsley, L Blower, A Agyeman, P Ranganathan, ...
Blood advances 2 (20), 2619-2628, 2018
Tocilizumab for steroid refractory acute graft-versus-host disease
JVF Roddy, BM Haverkos, A McBride, KM Leininger, S Jaglowski, ...
Leukemia & lymphoma 57 (1), 81-85, 2016
Impact of diagnostic genetics on remission MRD and transplantation outcomes in older patients with AML
HM Murdock, HT Kim, N Denlinger, P Vachhani, B Hambley, BS Manning, ...
Blood, The Journal of the American Society of Hematology 139 (24), 3546-3557, 2022
The interleukin-3 receptor CD123 targeted SL-401 mediates potent cytotoxic activity against CD34+ CD123+ cells from acute myeloid leukemia/myelodysplastic syndrome patients and†…
R Mani, S Goswami, B Gopalakrishnan, R Ramaswamy, R Wasmuth, ...
Haematologica 103 (8), 1288, 2018
Selective and potent CDK8/19 inhibitors enhance NK-cell activity and promote tumor surveillance
MH Hofmann, R Mani, H Engelhardt, MA Impagnatiello, S Carotta, ...
Molecular cancer therapeutics 19 (4), 1018-1030, 2020
The system can't perform the operation now. Try again later.
Articles 1–20